CTD kinases are critical for the elongation of HIV transcription and co-transcriptional processing of viral transcripts. They function after chromatin remodeling and before translation of viral proteins. Thus, our project will interface well with those of Greene, Ott and Verdin on epigenetic regulation ofthe integrated provirus. Manipulations that change the HIV epigenome will then be evaluated with respect to their effects on CTD kinases, for which we not only have the reagents but also a greater understanding of their function. It is more than likely that high throughput screens in these other projects will identify compounds that will affect P-TEFb, CycK or CycL complexes, or that will act in concert with agonists that affect primarily these CTD kinases'. In addition, studies by Karn on effects of cellular signaling on P-TEFb and NF-kB will allow us to his latency model to test our ideas on CycK and CycL complexes as well. It is also possible that effects of Nef are not mediated via P-TEFb but rather disregulate subunits of CycK, By differentially affecting HIV splicing and polyadenylation, they might allow more cells to enter proviral latency.

Public Health Relevance

The projects in mouse and macaque models in the HIV Collaboratory will directly contribute to several Important objectives ofthe Collaboratory including identification of the range of cells and tissues harboring latent proviruses, dissection of molecular mechanisms underlying HIV latency, and discovery and evaluation of new compounds and strategies for successfully purging the virus from the latent reservoirs or establishing a drug-free remission

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
1U19AI096113-01
Application #
8326787
Study Section
Special Emphasis Panel (ZAI1-JBS-A (M1))
Project Start
2011-07-08
Project End
2016-06-30
Budget Start
2011-07-08
Budget End
2012-06-30
Support Year
1
Fiscal Year
2011
Total Cost
$334,036
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
White, Cory H; Beliakova-Bethell, Nadejda; Lada, Steven M et al. (2018) Transcriptional Modulation of Human Endogenous Retroviruses in Primary CD4+ T Cells Following Vorinostat Treatment. Front Immunol 9:603
Chaillon, Antoine; Gianella, Sara; Lada, Steven M et al. (2018) Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. J Virol 92:
Jiang, Guochun; Nguyen, Don; Archin, Nancie M et al. (2018) HIV latency is reversed by ACSS2-driven histone crotonylation. J Clin Invest 128:1190-1198
Dubé, Karine; Dee, Lynda; Evans, David et al. (2018) Perceptions of Equipoise, Risk-Benefit Ratios, and ""Otherwise Healthy Volunteers"" in the Context of Early-Phase HIV Cure Research in the United States: A Qualitative Inquiry. J Empir Res Hum Res Ethics 13:3-17
Prakash, Katya; Gianella, Sara; Dubé, Karine et al. (2018) Willingness to participate in HIV research at the end of life (EOL). PLoS One 13:e0199670
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Honeycutt, Jenna B; Liao, Baolin; Nixon, Christopher C et al. (2018) T cells establish and maintain CNS viral infection in HIV-infected humanized mice. J Clin Invest 128:2862-2876
Power, Jennifer; Westle, Andrew; Dowsett, Gary W et al. (2018) Perceptions of HIV cure research among people living with HIV in Australia. PLoS One 13:e0202647
Marsden, Matthew D; Wu, Xiaomeng; Navab, Sara M et al. (2018) Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents. Virology 520:83-93
Beliakova-Bethell, Nadejda; Hezareh, Marjan; Wong, Joseph K et al. (2017) Relative efficacy of T cell stimuli as inducers of productive HIV-1 replication in latently infected CD4 lymphocytes from patients on suppressive cART. Virology 508:127-133

Showing the most recent 10 out of 221 publications